GlassScriptPhysician profile
Vishal D Desai
NPI 1104189661
$92,311.64
in general payments reported to CMS, 2019-2025
23 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $24K · 2021: $57K · 2022: $9,120 · 2023: $410 · 2024: $554 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634 · Travel and Lodging: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.70 |
| Travel and Lodging | $632.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $65,828.22 | 2021-2025 | Interstim |
| Covidien LP | $23,953.13 | 2019-2020 | |
| Stryker Corporation | $813.05 | 2025 | Alphavent, Iconix, Hipcheck |
| Abbvie INC. | $564.44 | 2022-2025 | Skyrizi, Mavyret, Rinvoq |
| Boston Scientific Corporation | $192.59 | 2024 | Capio Rp |
| Zimmer Biomet Holdings, INC. | $163.53 | 2019-2021 | |
| Janssen Biotech, INC. | $151.73 | 2019-2025 | Stelara, Tremfya |
| Aimmune Therapeutics, INC. | $124.99 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.62 | 2021-2025 | Entyvio |
| Pfizer INC. | $79.60 | 2024-2025 | |
| Evoke Pharma, INC. | $52.97 | 2023-2025 | Gimoti |
| Celgene Corporation | $39.27 | 2023 | Zeposia |
| Melinta Therapeutics, LLC | $36.21 | 2019 | |
| Merck Sharp & Dohme LLC | $29.38 | 2024 | Dificid |
| Madrigal Pharmaceuticals | $29.25 | 2025 | Rezdiffra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $27.97 | 2023 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.00 | 2023 | Cyltezo |
| Vivus LLC | $21.25 | 2024 | Pancreaze |
| Redhill Biopharma INC. | $19.58 | 2020 | |
| Lilly USA, LLC | $17.92 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $17.45 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $15.07 | 2024 | |
| Ambu INC. | $10.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishal Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.